Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial updates on its research and development (R&D) efforts and promising results from a Phase 1 dose-escalation study. Despite the recent surge, the stock remains down about 5% for the year, […]
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, has secured a pivotal acquisition by agreeing to purchase CN201, an investigational B-cell depletion therapy, from Curon Biopharmaceutical for $700 million in cash. This acquisition highlights Merck’s commitment to enhancing its oncology pipeline with cutting-edge therapies. Strategic Acquisition Enhances Merck’s […]
In a landmark decision, the US Food and Drug Administration (FDA) has extended its approval of Jemperli (dostarlimab) to include all adult patients with primary advanced or recurrent endometrial cancer. This expanded approval now encompasses patients with mismatch repair proficient (MMRp) or microsatellite stable (MSS) tumours, which account for the majority of endometrial cancer cases. […]
Affimed N.V. (Nasdaq: AFMD), a pioneering immuno-oncology company, has released compelling clinical data from its ongoing AFM24-102 study, showcasing significant advances in treating non-small cell lung cancer (NSCLC). This data, involving both EGFR wild-type (EGFRwt) and mutated (EGFRmut) NSCLC cohorts, marks a pivotal step in leveraging the innate immune system to combat cancer effectively. Clinical […]
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO (cemiplimab), in patients with solid tumors. This partnership marks a significant step in cancer research, potentially leading to more effective treatments for patients suffering […]
10x Genomics, Inc. (Nasdaq: TXG), a pioneering company in single cell and spatial biology, has announced the commercial release of its Xenium multi-modal cell segmentation kit alongside a newly optimized Xenium gene panel for immuno-oncology applications. These advancements mark a significant extension of the Xenium platform’s capabilities, solidifying its position as a leading tool for […]
In a notable advancement in the oncology sector, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a globally recognized oncology company, has received approval from the U.S. Food and Drug Administration (FDA) for TEVIMBRA (tislelizumab-jsgr). This approval marks a significant milestone for TEVIMBRA as a monotherapy in the treatment of adult patients with unresectable or […]
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono research and development (R&D) facility located in Billerica, Massachusetts. This expansion, which includes the construction of a new building, is set to drive innovations in critical areas like oncology, immuno-oncology, and immunology, helping the company advance its […]
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic move is the culmination of a collaborative partnership established between the two companies in 2015, aimed at advancing novel immuno-oncology (IO) therapies. Under the terms of the acquisition, Astellas has […]
Irish biopharmaceutical company Alkermes has announced an expansion of its ongoing Phase 1 trial to evaluate the safety and anti-tumor activity of its immuno-oncology drug ALKS 4230 in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab). This trial aims to explore the potential of this combination therapy in treating advanced solid tumors. ALKS 4230 is an […]